Review: The Role of Intestinal Dysbiosis in Parkinson’s Disease

Frontiers in Cellular and Infection Microbiology

Xiaodong Cai¹  Yiying Huang²  Xu Liu²  Jinchi Liao²  Ling Long²  Yunxiao Zhong² 

[1] Department of Neurology, Sixth Affiliated Hospital, Sun Yat-Sen University (Guangdong Gastrointestinal and Anal Hospital), Guangzhou, China;Department of Neurology, Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China;

关键词: Parkinson’s disease;    intestinal dysbiosis;    α-synuclein;    inflammation;    molecular mimicry;   

DOI  :  10.3389/fcimb.2021.615075

来源: Frontiers

【 摘 要 】

Several studies have highlighted the roles played by the gut microbiome in central nervous system diseases. Clinical symptoms and neuropathology have suggested that Parkinson’s disease may originate in the gut, which is home to approximately 100 trillion microbes. Alterations in the gastrointestinal microbiota populations may promote the development and progression of Parkinson’s disease. Here, we reviewed existing studies that have explored the role of intestinal dysbiosis in Parkinson’s disease, focusing on the roles of microbiota, their metabolites, and components in inflammation, barrier failure, microglial activation, and α-synuclein pathology. We conclude that there are intestinal dysbiosis in Parkinson’s disease. Intestinal dysbiosis is likely involved in the pathogenesis of Parkinson’s disease through mechanisms that include barrier destruction, inflammation and oxidative stress, decreased dopamine production, and molecular mimicry. Additional studies remain necessary to explore and verify the mechanisms through which dysbiosis may cause or promote Parkinson’s disease. Preclinical studies have shown that gastrointestinal microbial therapy may represent an effective and novel treatment for Parkinson’s disease; however, more studies, especially clinical studies, are necessary to explore the curative effects of microbial therapy in Parkinson’s disease.

【 授权许可】

CC BY